The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence

W. Polkowski, J. J B Van Lanschot, F. J W Ten Kate, J. P A Baak, G. N. Tytgat, H. Obertop, W. J. Voorn, G. J A Offerhaus

Research output: Contribution to journalArticle

Abstract

In the Barrett's oesophagus (BE) progression from metaplasia, via dysplasia, into invasive cancer, an aberrant cell proliferation governed by genetic change plays a central role. Alterations of the p53 tumour-suppressor gene appear especially critical and, like the proliferation marker Ki67, can be detected by immunohistochemistry. The purpose of this study therefore was to investigate the clinical value of p53 and Ki67 as markers for tumour progression in BE, and at the same time test the validity of the concept of a metaplasia-dysplasia-carcinoma sequence in BE by correlating the expression of these markers with various grades of dysplasia. Thirty-two lesions (seven negative for dysplasia, five indefinite for dysplasia, 11 low-grade dysplasia and nine high-grade dysplasia) from 25 archival resection specimens were selected for study. Increasing grades of dysplasia showed increasingly p53 accumulation; p53 accumulation was never observed in mucosa without dysplasia. The increasing p53 expression was accompanied by an increased Ki67-labelling index and an upward shift of the proliferative compartment. The results lend support to the multistep progression model of a metaplasia-dysplasia-carcinoma sequence in BE. Expression of p53 and Ki67, markers which can be easily applied on archival material, can be valuable adjuncts for the histopathological diagnosis of dysplasia and may have predictive value for cancer risk.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalSurgical Oncology
Volume4
Issue number3
StatePublished - 1995
Externally publishedYes

Fingerprint

Barrett Esophagus
Tumor Biomarkers
Metaplasia
Carcinoma
Tumor Suppressor Genes
Neoplasms
Mucous Membrane
Immunohistochemistry
Cell Proliferation

Keywords

  • Barrett
  • Carcinoma
  • Dysplasia
  • Ki67 antibody
  • p53 suppressor gene

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Polkowski, W., Van Lanschot, J. J. B., Ten Kate, F. J. W., Baak, J. P. A., Tytgat, G. N., Obertop, H., ... Offerhaus, G. J. A. (1995). The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surgical Oncology, 4(3), 163-171.

The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. / Polkowski, W.; Van Lanschot, J. J B; Ten Kate, F. J W; Baak, J. P A; Tytgat, G. N.; Obertop, H.; Voorn, W. J.; Offerhaus, G. J A.

In: Surgical Oncology, Vol. 4, No. 3, 1995, p. 163-171.

Research output: Contribution to journalArticle

Polkowski, W, Van Lanschot, JJB, Ten Kate, FJW, Baak, JPA, Tytgat, GN, Obertop, H, Voorn, WJ & Offerhaus, GJA 1995, 'The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence', Surgical Oncology, vol. 4, no. 3, pp. 163-171.
Polkowski W, Van Lanschot JJB, Ten Kate FJW, Baak JPA, Tytgat GN, Obertop H et al. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surgical Oncology. 1995;4(3):163-171.
Polkowski, W. ; Van Lanschot, J. J B ; Ten Kate, F. J W ; Baak, J. P A ; Tytgat, G. N. ; Obertop, H. ; Voorn, W. J. ; Offerhaus, G. J A. / The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. In: Surgical Oncology. 1995 ; Vol. 4, No. 3. pp. 163-171.
@article{016e785b50f249088998476a66dcbe2d,
title = "The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence",
abstract = "In the Barrett's oesophagus (BE) progression from metaplasia, via dysplasia, into invasive cancer, an aberrant cell proliferation governed by genetic change plays a central role. Alterations of the p53 tumour-suppressor gene appear especially critical and, like the proliferation marker Ki67, can be detected by immunohistochemistry. The purpose of this study therefore was to investigate the clinical value of p53 and Ki67 as markers for tumour progression in BE, and at the same time test the validity of the concept of a metaplasia-dysplasia-carcinoma sequence in BE by correlating the expression of these markers with various grades of dysplasia. Thirty-two lesions (seven negative for dysplasia, five indefinite for dysplasia, 11 low-grade dysplasia and nine high-grade dysplasia) from 25 archival resection specimens were selected for study. Increasing grades of dysplasia showed increasingly p53 accumulation; p53 accumulation was never observed in mucosa without dysplasia. The increasing p53 expression was accompanied by an increased Ki67-labelling index and an upward shift of the proliferative compartment. The results lend support to the multistep progression model of a metaplasia-dysplasia-carcinoma sequence in BE. Expression of p53 and Ki67, markers which can be easily applied on archival material, can be valuable adjuncts for the histopathological diagnosis of dysplasia and may have predictive value for cancer risk.",
keywords = "Barrett, Carcinoma, Dysplasia, Ki67 antibody, p53 suppressor gene",
author = "W. Polkowski and {Van Lanschot}, {J. J B} and {Ten Kate}, {F. J W} and Baak, {J. P A} and Tytgat, {G. N.} and H. Obertop and Voorn, {W. J.} and Offerhaus, {G. J A}",
year = "1995",
language = "English (US)",
volume = "4",
pages = "163--171",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence

AU - Polkowski, W.

AU - Van Lanschot, J. J B

AU - Ten Kate, F. J W

AU - Baak, J. P A

AU - Tytgat, G. N.

AU - Obertop, H.

AU - Voorn, W. J.

AU - Offerhaus, G. J A

PY - 1995

Y1 - 1995

N2 - In the Barrett's oesophagus (BE) progression from metaplasia, via dysplasia, into invasive cancer, an aberrant cell proliferation governed by genetic change plays a central role. Alterations of the p53 tumour-suppressor gene appear especially critical and, like the proliferation marker Ki67, can be detected by immunohistochemistry. The purpose of this study therefore was to investigate the clinical value of p53 and Ki67 as markers for tumour progression in BE, and at the same time test the validity of the concept of a metaplasia-dysplasia-carcinoma sequence in BE by correlating the expression of these markers with various grades of dysplasia. Thirty-two lesions (seven negative for dysplasia, five indefinite for dysplasia, 11 low-grade dysplasia and nine high-grade dysplasia) from 25 archival resection specimens were selected for study. Increasing grades of dysplasia showed increasingly p53 accumulation; p53 accumulation was never observed in mucosa without dysplasia. The increasing p53 expression was accompanied by an increased Ki67-labelling index and an upward shift of the proliferative compartment. The results lend support to the multistep progression model of a metaplasia-dysplasia-carcinoma sequence in BE. Expression of p53 and Ki67, markers which can be easily applied on archival material, can be valuable adjuncts for the histopathological diagnosis of dysplasia and may have predictive value for cancer risk.

AB - In the Barrett's oesophagus (BE) progression from metaplasia, via dysplasia, into invasive cancer, an aberrant cell proliferation governed by genetic change plays a central role. Alterations of the p53 tumour-suppressor gene appear especially critical and, like the proliferation marker Ki67, can be detected by immunohistochemistry. The purpose of this study therefore was to investigate the clinical value of p53 and Ki67 as markers for tumour progression in BE, and at the same time test the validity of the concept of a metaplasia-dysplasia-carcinoma sequence in BE by correlating the expression of these markers with various grades of dysplasia. Thirty-two lesions (seven negative for dysplasia, five indefinite for dysplasia, 11 low-grade dysplasia and nine high-grade dysplasia) from 25 archival resection specimens were selected for study. Increasing grades of dysplasia showed increasingly p53 accumulation; p53 accumulation was never observed in mucosa without dysplasia. The increasing p53 expression was accompanied by an increased Ki67-labelling index and an upward shift of the proliferative compartment. The results lend support to the multistep progression model of a metaplasia-dysplasia-carcinoma sequence in BE. Expression of p53 and Ki67, markers which can be easily applied on archival material, can be valuable adjuncts for the histopathological diagnosis of dysplasia and may have predictive value for cancer risk.

KW - Barrett

KW - Carcinoma

KW - Dysplasia

KW - Ki67 antibody

KW - p53 suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0029119205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029119205&partnerID=8YFLogxK

M3 - Article

C2 - 7582189

AN - SCOPUS:0029119205

VL - 4

SP - 163

EP - 171

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 3

ER -